检索结果-南通市图书馆

Acta Pharmacologica Sinica 2007年第3期28卷 453-458页

作者： li-cheng dai~(2,5) xiang wang~2 xing yao~3 li-shan min~3 jin-liang ping~4 jian-fang he~2 ~2huzhou key laboratory of molecular medicine,~3Department of General Surgery and ~4Department of Pathology Huzhou Central Hospital,Huzhou 313000,China huzhoukeylaboratoryofmolecularmedicine HuzhouCentralHospitalHuzhou313000China departmentofgeneralsurgery HuzhouCentralHospitalHuzhou313000China departmentofpathology HuzhouCentralHospitalHuzhou313000China

Aim:To evaluate the in vivo antitumor effects of antisense oligonucleotides tar-geting midkine(MK-AS).Methods:An in situ human hepatocellular carcinoma(HCC)model was established in mice livers orthotopically.The MK-AS and 5-fluorouracil(5-Fu)were administered intravenously.The tumor sizes and plasmaalpha-fetoprotein(AFP)were measured by calipers and radiation immunoassayrespectively.The morphology of tumors was evaluated by hematoxylin-eosinstaining of histological sections.Human MK,p53,Bax,Bcl-2,and caspase-3protein content were detected by Western blotting.Results:MK-AS signifi-cantly inhibited in situ human HCC growth in mice compared with the saline groupin a dose-dependent manner.After the treatment with MK-AS or with 5-Fu,theplasma AFP concentration decreased in a dose-dependent manner.Interestingly,MK-AS also clearly downregulated the protein level of Bcl-2,and upregulatedp53,Bax,and caspase-3 in the hepatocellular carcinoma tissue.Conclusion:Theseresults demonstrated that MK-AS was an effective antitumor antisense oligo-nucleotide in vivo in mice;its antitumor effect is associated with the increase ofpro-apoptotic proteins,such as p53,Bax,and caspase-3,and the decrease of theanti-apoptotic protein,Bcl-2.

关键词： oligonucleotides antisense midkine carcinoma hepatocellular

Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Acta Pharmacologica Sinica 2006年第12期27卷 1630-1636页

作者： li-cheng dai~(2,5)xiang wang~2 xing yao~3 Yong-liang LU~3 jin-liang ping~4 jian-fang he~2 2 huzhou key laboratory of molecular medicine,3 department of general surgery,4 department of pathology,huzhou central hospital,Huzhou 313000,China huzhoukeylaboratoryofmolecularmedicine departmentofgeneralsurgery departmentofpathology HuzhouCentralHospitalHuzhou313000China

Aim:Overexpression of midkine(MK)has been observed in many malignancies.This aim of this study is to screen for suitable antisense oligonucleotides(ASODN)targeting MK in hepatocellular carcinoma(HCC)cells and evaluate its antitumoractivity.Methods:Ten ASODN targeting MK were designed and synthesized.After transfection with ASODN,cell proliferation was analyzed with MTS[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,inner salt]assay.In addition,MK mRNA,protein levels,as well asapoptosis and caspase-3 activity were also examined in hepG2 cells.Cell prolif-eration was then analyzed after treatment with both ASODN and chemotherapeu-tic drugs.Results:In this experiment,the ASODN5 among the 10 ASODN showedhigher inhibitory activity against proliferation of hepatocellular carcinoma cells ina dose-dependent manner.In hepG2 cells,ASODN5 could significantly reducethe MK mRNA level and protein content.After transfection with ASODN5 for48h,accompanied with a decline of survivin and Bcl-2 protein content,a remark-able increase of apoptosis and caspase-3 activity was observed in hepG2 cells.Furthermore,ASODN5 transfer can significantly increase chemosensitivity inhepG2 cells.Conclusion:Antisense oligonucleotides targeting MK shows thera-peutic effects on HCC;ASODN5 has the possibility to be developed as an effec-tive antitumor agent.

关键词： antisense oligonucleotide midkine apoptosis hepatocellular carcinoma chemosensitivity

Antisense oligonucleotide targeting p53 increased apoptosis of MCF-7 cells induced by ionizing radiation

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Acta Pharmacologica Sinica 2006年第11期27卷 1453-1458页

作者： li-cheng dai~2 xiang wang xing yao li-shan min Fu-chu QIAN jian-fang he huzhou key laboratory of molecular medicine,huzhou central hospital,Huzhou 313000,China huzhou key laboratory of molecular medicine Huzhou Central Hospital Huzhou 313000 China. dlc@***

Aim:To investigate the effect of antisense compounds(AS)targeting human p53mRNA on radiosensitivity of MCF-7 cells.Methods:Western blotting and RT-PCR were used to analyze the protein content and mRNA level.Additionally,cellproliferation,cell cycle and cell apoptosis were all analyzed in irradiated or sham-irradiated cells.Results:Among the five antisense compounds(AS),AS3 wasidentified to efficiently inhibit p53 mRNA level and protein content.Interestingly,AS3 transfer has little effect on cell proliferation in DU-145 cells(mutant p53)afterionizing radiation(IR).In contrast,a marked increase of cell apoptosis and growthinhibition were observed in MCF-7 cells(wild-type p53),suggesting that AS3 canincrease radiosensitivity of MCF-7 cells.Additionally,it was also observed thatthe transfection of AS3 decreased the fraction of G1phase cells,and increased theproportion of S phase cells compared to untreated cells 24 h after IR in MCF-7 celllines.Conclusion:AS3 transfection increases MCF-7 cell apoptosis induced by5 Gy-radiation,and this mechanism may be closely associated with abrogation ofG1phase arrest.

关键词： antisense oligodeoxyribonucleotides MCF-7 p53 genes radiation tolerance cell cycle

Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2007年第8期13卷 1208-1213页

作者： li-cheng dai xiang wang xing yao Yong-liang Lu jin-liang ping jian-fang he huzhou key laboratory of molecular medicine Huzhou Central Hospital Huzhou 313000 Zhejiang Province China department of general surgery Huzhou Central Hospital Huzhou 313000 Zhejiang Province China department of pathology Huzhou Central Hospital Huzhou 313000 Zhejiang Province China

AIM: To evaluate the effect of antisense oligonucleotide targeting midkine (MK-AS) on angiogenesis in chick chorioallantoic membrane (CAM) and in situ human hepatocellular carcinoma (HCC). METHODS: An in situ human hepatocellular carcinoma (HCC) model and CAM assay were used in this experiment. The effect of MK-AS on angiogenesis was evaluated by cell proliferation assay and hematoxylin- eosin (he) staining. RESULTS: MK-AS significantly inhibited human umbilical vein endothelial cells (HUVEC) and in situ human HCC growth. At the same time, MK-AS suppressed the angiogenesis both in human hepatocellular carcinoma cell line (hePG2)-induced CAM and in situ human HCC tissues. CONCLUSION: MK-AS is an effective antiangiogenesis agent in vivo.

关键词：中期因子肿瘤血管发生反义寡核苷酸抑制作用靶点

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Integrative medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang Yue-yi Deng Wei li Ya-ni he Zhao-hui Ni Yong-li Zhan shan lin Zhi-yong Guo Jun Zhu jing-ai fang Xu-sheng liu li-hua wang Rong wang Nian-song wang Xiao-hong cheng li-qun he ping Luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru jiang Hong-yu Chen Wen-hu liu Hong-li lin Meng liang Lu Ma ming Chen li-qun Song jian Chen Qing Zhu Chang-ying xing Yun li Ji-ning Gao Rong-shan li Ying li Hao Zhang Ying Lu Qiao-ling Zhou Jun-zhou Fu Qiang he Guang-yan Cai xiang-mei Chen department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China department of Nephrology Tianjin Medical University General HospitalTianjin 300052China department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney disease.Objective:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan potassium.Design,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical trial.Primary glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 mg.Main outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of treatment.Results:A total of 735 participants were enrolled.The percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg group.Compared with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Phe losartan potassium 100 mg group,the SYKFT plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine protein.With a superiority threshold of 15%,neither was statistically significant.eGFR,serum creatinine and serum albumin from the baseline did not change statistically significant.The average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any group.Conclusion:SYKFT decreased the proteinuria and improved the TCM syndrome scores of prima

关键词： herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

维普期刊数据库

Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2013年第12期126卷 2276-2280页

作者： ZheNG Ying CAI Guang-yan CheN xiang-mei FU ping CheN jiang-hua DING Xiao-qiang YU Xue-qing liN Hong-li liU jian XIE Ru-juan wang li-ning NI Zhao-hui liU Fu-you YIN Ai-ping xing Chang-ying wang li SHI Wei liU jian-she he Ya-ni DING Guo-hua li Wen-ge WU Guang-li MIAO li-ning CheN Nan SU Zhen MEI Chang-lin ZHAO Jiu-yang GU Yong BAI Yun-kai LUO Hui-min liN shan CheN Meng-hua GONG li YANG Yi-bin YANG Xiao-ping li Ying WAN jian-xin wang Nian-song li Hai-ying XI Chun-sheng HAO li XU Yan fang jing-ai liU Bi-cheng li Rong-shan wang Rong ZHANG jing-hong wang jian-qin LOU Tan-qi SHAO Feng-min MEI Feng liU Zhi-hong YUAN Wei-jie SUN Shi-ren ZHANG ling ZHOU Chun-hua CheN Qin-kai JIA Shun-lian GONG Zhi-feng GUAN Guang-ju XIA Tian ZHONG liang-bao department of Nephrology State key Laboratory of Kidney Disease Chinese PLA General Hospital Beijing 100853 China Nephrology Institute of the Chinese People's liberation Army Chinese People's Liberation Army Key Laboratory of Nephrology Beijing 100853 China department of Nephrology West China Hospital of Sichuan University Chengdu Sichuan 610041 China department of Nephrology First Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310003 China department of Nephrology Zhongshan Hospital Fudan University Shanghai 200032 China department of Nephrology First Affiiated Hospital of Sun Yat-sen University Guangzhou Guangdong 510080 China department of Nephrology First Affiliated Hospital of Dalian Medical University Dalian Liaoning 116011 China department of Nephrology First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China department of Nephrology First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150001 China department of Nephrology First Afftiated Hospital of China Medical University Shenyang Liaoning 110001 China department of Nephrology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200025 China department of Nephrology Second Xiangya Hospital Central South University Changsha Hunan 410000 China department of Nephrology First Affiliated Hospital of Medical College Xi'an Jiaotong University Xi'an Shaanxi 710061 China department of Nephrology First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) Nanjing Jiangsu 210029 China department of Nephrology Sichuan Provincial People's Hospital Chengdu Sichuan 610072 China department of Nephrology Guangdong Provincial People's Hospital Guangzhou Guangdong 510030 China department of Nephrology Affliated Xiehe Hospital Tongji Medical College Huazhong Science and Technology University Wuhan Hubei 430022 China department of Nephrology Daping Hospital Third Military Medi

Background Data on the epidemiology of hypertension in Chinese non-dialysis chronic kidney disease （CKD） patients are limited.The aim of the present study was to investigate the prevalence,awareness,treatment,and control of hypertension in the non-dialysis CKD patients through a nationwide,multicenter study in China.Methods The survey was performed in 61 tertiary hospitals in 31 provinces,municipalities,and autonomous regions in China （except Hong Kong,Macao,and Taiwan）.Trained physicians collected demographic and clinical data and measured blood pressure （BP） using a standardized protocol.Hypertension was defned as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg,and/or use of antihypertensive medications.BP 〈140/90 mmHg and 〈130/80 mmHg were used as the 2 thresholds of hypertension control.In multivariate logistic regression with adjustment for sex and age,we analyzed the association between CKD stages and uncontrolled hypertension in non-dialysis CKD patients.Results The analysis included 8927 non-dialysis CKD patients.The prevalence,awareness,and treatment of hypertension in non-dialysis CKD patients were 67.3%,85.8%,and 81.0%,respectively.Of hypertensive CKD patients,33.1% and 14.1% had controlled BP to 〈140/90 mmHg and 〈130/80 mmHg,respectively.With successive CKD stages,the prevalence of hypertension in non-dialysis CKD patients increased,but the control of hypertension decreased （P〈0.001）.When the threshold of BP 〈130/80 mmHg was considered,the risk of uncontrolled hypertension in CKD 2,3a,3b,4,and 5 stages increased 1.3,1.4,1.4,2.5,and 4.0 times compared with CKD 1 stage,respectively （P〈0.05）.Using the threshold of 〈140/90 mmHg,the risk of uncontrolled hypertension increased in advanced stages （P〈0.05）.Conclusions The prevalence of hypertension Chinese non-dialysis CKD patients was high,and the hypertension control was suboptimal.With successive CKD stages,the risk of uncontrolled hypertension increased.

关键词： non-dialysis chronic kidney disease chronic kidney disease stages hypertension epidemiology

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： Hai-Dong Zhu Hai-liang li ming-Sheng Huang Wei-Zhu Yang Guo-Wen Yin Bin-Yan Zhong Jun-Hui Sun Zhi-cheng jin jian-jian Chen Nai-jian Ge Wen-Bin Ding Wen-Hui li jin-Hua Huang Wei Mu shan-Zhi Gu Jia-ping li Hui Zhao Shu-Wei Wen Yan-ming Lei Yu-Sheng Song Chun-wang Yuan Wei-Dong wang ming Huang Wei Zhao jian-Bing Wu Song wang Xu Zhu jian-Jun Han Wei-Xin Ren Zai-ming Lu Wen-Ge xing Yong Fan Hai-Lan lin Zi-Shu Zhang Guo-Hui Xu Wen-Hao Hu Qiang Tu Hong-Ying Su Chuan-Sheng Zheng Yong Chen Xu-Ya Zhao Zhu-Ting fang Qi wang jin-Wei Zhao Ai-Bing Xu jian Xu Qing-Hua Wu Huan-Zhang Niu jian wang Feng dai Dui-ping Feng Qing-Dong li Rong-Shu Shi Jia-Rui li Guang Yang Hai-Bin Shi jian-Song Ji Yu-E liu Zheng Cai Po Yang Yang Zhao Xiao-li Zhu li-Gong Lu Gao-Jun Teng Center of Interventional Radiology&Vascular surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China department of minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China department of Interventional Radiology Nantong First People’s HospitalNantong 226001China department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China department of minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China department of Vascular surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations.In this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May 2021.The primary endpoint was progression-free survival(PFS)according to modified RECIST.The secondary outcomes included overall survival(OS),objective response rate(ORR),and safety.We performed propensity score matching approaches to reduce bias between two groups.After matching,228 pairs were included with a predominantly advanced disease population.Median PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;P3/4 adverse events were observed at a rate of 15.8%and 7.5%in combination and monotherapy groups,respectively.Our results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

Frequent RNF43 mutation contributes to moderate activation of Wnt signaling in colorectal signet-ring cell carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Protein & Cell 2020年第4期11卷 292-298页

作者： Yaqi li jian li Renjie wang Long Zhang Guoxiang Fu Xueying wang Yebin wang Chuantao fang Dandan Zhang Duo Du Xiaoji Ma Mengxue Pan Qiang Guo Xiaoya Xu xiang Hu Yi Zhou Shaobo Mo Huijun wang jianjun Gao Shenglin Huang Yun liu Sanjun Cai Guoqiang Hua Junjie Peng Fa-xing Yu department of Colorectal surgery Fudan University Shanghai Cancer CenterShanghai 200032China department of Oncology Shanghai Medical CollegeFudan UniversityShanghai 200032China Institute of Pediatrics Children's Hospital of Fudan UniversityShanghai 200032China key laboratory of Medical Epigenetics and Metabolism Institutes of Biomedical SciencesFudan UniversityShanghai 200032China Cancer Institute Fudan University Shanghai Cancer CenterFudan UniversityShanghai 200032China Institute of Radiation medicine Fudan UniversityShanghai 200032China MOE key laboratory of Metabolism and molecular medicine Department of Biochemistry and Molecular BiologySchool of Basic Medical SciencesFudan UniversityShanghai 200032China Fudan University shanghai Cancer Center and Institutes of Biomedical Sciences Shanghai Medical CollegeFudan UniversityShanghai 200032China Institute of Radiation medicine and Fudan University shanghai Cancer Center Shanghai Medical schoolFudan UniversityShanghai 200032China

Dear Editor,Signet-ring cell carcinoma(SRCC)is a rare subtype of colorectal cancer(CRC)characterized histologically by the accumulation of mucins in the cytoplasm and displacement of nuclei to the cellular periphery,accounting for about 1%CRC(Fig.S1A)(Borger et al.,2007).Compare to common subtypes of CRC,such as adenocarcinoma(AC)and mucinous adenocarcinoma(MAC),SRCC is associated with aggressive behaviors and younger age at presentation(Kang et al.,2005;Sung et al.,2008;Nitsche et al.,2013;Hugen et al.,2014;Inamura et al.,2015).A retrospective analysis of CRC patient's data at Fudan University shanghai Cancer Center(FUSCC)also indicated a worse overall and disease-free survival of SRCC patients(Fig.S1B and S1C,Table S1).

关键词： al. colorectal adenocarcinoma

A five-compartment model of age-specific transmissibility of SARS-CoV-2

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Infectious Diseases of Poverty 2020年第4期9卷 35-49页

作者： Ze-Yu Zhao Yuan-Zhao Zhu jing-Wen Xu Shi-Xiong Hu Qing-Qing Hu Zhao Lei Jia Rui xing-Chun liu yao wang Meng Yang li Luo shan-shan Yu Jia li Ruo-Yun liu fang Xie Ying-Ying Su Yi-Chen Chiang Ben-Hua Zhao jing-An Cui ling Yin Yan-Hua Su Qing-Long Zhao li-Dong Gao Tian-Mu Chen State key laboratory of molecular Vaccinology and molecular Diagnostics School of Public HealthXiamen University4221-117 South Xiang'an RoadXiang'an DistrictXiamen City 361102Fujian ProvincePeople's Republic of China Hunan Provincial Center for Disease Control and Prevention 405 Furong Middle Road Section OneKaifu DistrictChangsha City 410001Hunan ProvincePeople's Republic of China Division of Public health School of MedicineUniversity of Utah201 Presidents CircleSalt Lake CityUT 84112USA department of Mathematics School of ScienceBeijing University of Civil Engineering and ArchitectureBeijingPeople's Republic of China Shenzhen Institutes of Advanced Technology Chinese Academy of SciencesShenzhenGuangdong ProvincePeople's Republic of China Jilin Provincial Center for Disease Control and Prevention 3145 Jingyang Big RoadLvyuan DistrictChangchun 130062Jilin ProvincePeople's Republic of China

Background:The novel coronavirus,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2,also called 2019-nCoV)causes different morbidity risks to individuals in different age groups.This study attempts to quantify the age-specific transmissibility using a mathematical model.Methods:An epidemiological model with five compartments(susceptible-exposed-symptomatic-asymptomatic-recovered/removed[SEIAR])was developed based on observed transmission features.Coronavirus disease 2019(COVID-19)cases were divided into four age groups:group 1,those≤14years old;group 2,those 15 to 44years old;group 3,those 45 to 64years old;and group 4,those≥65 years old.The model was initially based on cases(including imported cases and secondary cases)collected in Hunan Province from January 5 to February 19,2020.Another dataset,from Jilin Province,was used to test the model.Results:The age-specific SEIAR model fitted the data well in each age group(Phe highest transmissibility was from age group 4 to 3(median:β43=7.71×10-9;SAR43=3.86×10-8),followed by group 3 to 4(median:β34=3.07×10-9;SAR34=1.53×10-8),group 2 to 2(median:β22=1.24×10-9;SAR22=6.21×10-9),and group 3 to 1(median:β31=4.10×10-10;SAR31=2.08×10-9).The lowest transmissibility was from age group 3 to 3(median:β33=1.64×10-19;SAR33=8.19×10-19),followed by group 4 to 4(median:β44=3.66×10-17;SAR44=1.83×10-16),group 3 to 2(median:β32=1.21×10-16;SAR32=6.06×10-16),and group 1 to 4(median:β14=7.20×10-14;SAR14=3.60×10-13).In Jilin Province,the highest transmissibility occurred from age group 4 to 4(median:β43=4.27×10-8;SAR43=2.13×10-7),followed by group 3 to 4(median:β34=1.81×10-8;SAR34=9.03×10-8).Conclusions:SARS-CoV-2 exhibits high transmissibility between middle-aged(45 to 64 years old)and elderly(≥65 years old)people.Children(≤14 years old)have very low susceptibility to COVID-19.This study will improve our understanding of the transmission feature of SARS-CoV-2 in different age groups and suggest the most prevention measures should be applied to middle-age

关键词： Transmissibility SARS-CoV-2 COVID-19 Compartmental model Age-specific dynamics

维普期刊数据库

Consensus statement on layout and delivery of automatic external defibrillator in China

在线全文

学校读者我要写书评

暂无评论

Journal of Hainan Medical University 2020年第15期26卷 18-23页

作者： Yu Cao Song Chen Yan-Fen Chai Xiao-Hui Chen Yu-Guo Chen Shao-Wen cheng Wen-Wei cheng Bang-Han Ding Yang Deng Jie Fu Bang-jiang fang Mai-Ying Fan li Gui ping Gong Wei Guo Shu-Bin Guo liang Huang Ji-Yuan Han Zhong Ji Xian-Fei Ji Xin-Cai Ji Hong-Xu jin Xin-Jun jiang wang-xiang jiang Jia-liang liu Xiao-Ran liu Zhi liu Chuan-Zhu Lv Feng Lu Tan-Shi li Xin li Yong li shang-Lun li Shuang-ming li Xiao-Gang li Bao-Jun li Pei-Wu li Chun-Sheng li Zhi-Jun li Chang-Luo li xiang-min li Yin-ping li Zong-Jun Lu Zu-Xun Lu Zhong-Qiu Lu Zhi-Qian Luo Xiao-xing liao jian-Bo Lei Tao Ma Yu Ma Yue-Feng Ma Qing-Bian Ma lin-Hao Ma Jun-Qi Ma Shi-Nan Nie Jie-Miao Ou-Yang Peng Peng Qiao Pei Shu-ming Pan Guo-Zhong Qing li-Jie Qin Wu-Ying Qiao Fei Shao Wei Song xing-Yue Song Zhen-Ju Song Rong-Ju Sun De-Ya shang Du-Juan Sha Gui-Lan Tao Guo-Gang Tian Ying-ping Tian jian-Guang Tian Chao-Yang Tong Zi-Ren Tang Meng-Xiong Tang Guo-ping Wu Zhi Wan Tao wang Xin wang Peng wang Zhong wang Tong wang Ri-xing wang Yi-Xin wang Xiao-Dan wang ling Wu Wei Wei Hua xiang Feng Xu Jun Xu Jie Xu Miao-Rong Xie Shuo-Gui Xu Tie Xu Feng Yu Wen Yi li-shan Yang Shi-Jiao Yan jin-jian yao Shou-Chun Yan Xue-Zhong Yu Xian-Zhi Ye Xian-liang Yan Fu-Bing Zhou Rong-Bin Zhou ming Zhou Qiang Zhou jin Zhou ping Zhou Chang-Ju Zhu Hua-Dong Zhu Ji-Hong Zhu Hong Zhang Mao Zhang Hua Zhang Na Zhang Guo-Qiang Zhang Guo-Xiu Zhang jin-Song Zhang Wen-Wu Zhang Wen-Zhong Zhang jian-Feng Zhang Yi-min Zhu Jun Zeng Yuan Zheng Zhi-Jie Zheng Shen Zhao Yan Zhao min Zhao Bin Zhao Xiao-Dong Zhao Xiao-jing Zhao Hong-Ke Zeng Sheng-Qiang Zou The Chinese Society of Emergency medicine Research Unit of Island Emergency medicine Chinese Academy of Medical SciencesHainan Medical University key laboratory of Emergency and Trauma of ministry of Education Hainan Medical UniversityHaikouHainanChina Emergency and Trauma College Hainan Medical UniversityHaikouHainanChina department of Emergency Hainan Clinical Research Center for Acute and Critical DiseasesThe Second Affiliated Hospital of Hainan Medical UniversityHaikouHainanChina key laboratory of Hainan Trauma and Disaster Rescue key laboratory of Trauma of Hainan Medical University

1.Introduction Sudden cardiac death(SCD)refers to sudden death due to a variety of cardiac causes.It is manifested as a sudden loss of consciousness,cardiac arrest,and respiratory arrest and generally shows early symptoms that are atypical and not easily detected[1].According to a recent study,nearly 544000 patients suffer from SCD every year in China[2].

关键词： cardiac death respiratory